GRIB. Research Unit on Biomedical Informatics





News & activities

Jordi Mestres, membre del Scientific Advisory Board del portal Chemical Probes

Felicitem a Jordi Mestres, coordinador del grup de recerca en Farmacologia de Sistemes del GRIB (IMIM-UPF) que ha estat escollit membre del Scientific Advisory Board del portal Chemical Probes, una eina accessible des d'internet i gratuïta que permet als investigadors, abans de començar una recerca, buscar la sonda química més apropiada per al seu projecte. Les sondes químiques o chemical probes, són unes molècules molt petites que interaccionen amb múltiples proteïnes i que tenen un impacte molt gran en la recerca biomèdica ja que si són de baixa qualitat, poden generar resultats científics erronis. Conèixer la interacció d'aquestes petites molècules, és clau en el desenvolupament de fàrmacs més eficients i segurs.

Aquest innovador portal recomana als investigadors sondes químiques basades en les aportacions del Scientific Advisory Board, un grup d'experts en el camp de la biologia química, medicina química, farmacologia i camps relacionats, que estan qualificats per determinar les millors sondes químiques disponibles i establir pautes adequades per a la seva utilització.

More info...

Graphical Abstract

Cancer cell lines predict drug response

Research published in Cell has shown that patient-derived cancer cell lines harbour most of the same genetic changes found in patients' tumours, and could be used to learn how tumours are likely to respond to new drugs, increasing the success rate for developing new personalised cancer treatments.

David Tamborero and Núria López-Bigas, members of the Biomedical Genomics group of GRIB (UPF-IMIM) have participated on this international study led by scientists from the Wellcome Trust Sanger Institute, the European Bioinformatics Institute (EMBL-EBI) and the Netherlands Cancer Institute, discovering a strong link between many mutations in patient cancer samples, and the sensitivity to particular drugs. This could advance personalised cancer medicine by leading to results that help doctors predict the best available drugs, or the most suitable clinical trials for each individual patient.

In the first systematic, large-scale study to combine molecular data from patients, laboratory cancer cell lines and drug sensitivity, David Tamborero says: "one of the main difficulties of the study was to interpret the large amount of genomic alterations observed in the tumor cells', and continue: "our task was to identify the mutations that are important for the development of each of the cancers in order to associate them with the observed drug responses".

Click here to read the full Press Release of the Wellcome Trust Sanger Institute. 

More info...

More news RSS

Last project

NONCODRIVERS

The project NONCODRIVERS "Finding noncoding cancer drivers", aims to characterize the role of mutations in non-coding regions in the most prevalent tumours of the population. The work will count with the collaboration of the International Cancer Genome Consortium, an organization created for the classification of the molecular profile of 50 different types of cancer. The project aims to identify those non-coding alterations that are more relevant for tumour biology through computational methods and will explore new therapeutic strategies that can revert its effects by means of the creation of the corresponding cellular models. The project​ is funded for the period 2016-2021 by the European Research Council (ERC) with an ERC Consolidator grants given to Nuria López-Bigas, head of the Biomedical Genomics group of GRIB.

http://bg.upf.edu/blog/2016/02/erc-consolidator-granted-to-our-lab-to-find-noncoding-cancer-drivers/

More projects

Last publications

  • Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ. A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016; pii: S0092-8674(16)30746-2. PMID: 27397505 . DOI: 10.1016/j.cell.2016.06.017.
  • Digles D, Zdrazil B, Neefs JM, Van Vlijmen H, Herhaus C, Caracoti A. Brea J, Roibas B, Loza MI, Queralt-Rosinach N, Furlong LI, Gaulton A, Bartek L, Senger S, Chichester C, Engkvist O, Evelo CT, Franklin NI, Marren D, Ecker GF, Jacoby E. Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns. MEDCHEMCOMM, 7 (6): 1237-1244 DOI: 10.1039/c6md00065g 2016.
  • Poglayen D, Marín-López MA, Bonet J, Fornes O, Garcia-Garcia J, Planas-Iglesias J, Segura J, Oliva B, Fernandez-Fuentes N. InteractoMIX: a suite of computational tools to exploit interactomes in biological and clinical research. Biochem Soc Trans, 2016; 44(3): 917-24. PMID: 27284060 . DOI: 10.1042/BST20150001.
  • Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Cuesta AM, Blanco-Toribio A, Harwood SL, Villate M, Merino N, Bonet J, Navarro R, Muñoz-Briones C, Sørensen KM, Mølgaard K, Oliva B, Sanz L, Blanco FJ, Alvarez-Vallina L. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Sci Rep, 2016; 6: 28643. PMID: 27345490 . DOI: 10.1038/srep28643.

More publications



Site Information